ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. It induces NO and iNOS production, enhances apoptosis, and immune surveillance. It also increases aortic atherosclerotic plaque size and exhibits antitumor activity against lung cancer, glioma, and melanoma.
- Induces nitric oxide and iNOS production in macrophages
- Enhances apoptosis and immune surveillance
- Increases aortic atherosclerotic plaque size in a chronic vascular injury mouse model
- Exhibits antitumor activity against lung cancer, glioma, and melanoma
- Delays growth of subcutaneously implanted gliomas and increases infiltration of macrophages and B cells into tumors